A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols
Sebastian Attig(Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz), Cedrik M. Britten(Johannes Gutenberg University Mainz), Michael Kalos(Pillar College), Sylvia Janetzki(Yale University), T. M. Clay(Duke Medical Center), Leah Price(Cwm Taf University Health Board), Michael W. Pride(Pfizer (United States)), Axel Hoos(GlaxoSmithKline (United States)), Jianda Yuan, Pedro Romero(TiGenix (Spain)), Kunle Odunsi(University of Chicago), Lisa K. McNeil
Cited by 25
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k